J. Harvey Turner

3.9k total citations
101 papers, 2.6k citations indexed

About

J. Harvey Turner is a scholar working on Radiology, Nuclear Medicine and Imaging, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Harvey Turner has authored 101 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Radiology, Nuclear Medicine and Imaging, 19 papers in Epidemiology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Harvey Turner's work include Radiopharmaceutical Chemistry and Applications (28 papers), Neuroendocrine Tumor Research Advances (18 papers) and Research in Cotton Cultivation (15 papers). J. Harvey Turner is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (28 papers), Neuroendocrine Tumor Research Advances (18 papers) and Research in Cotton Cultivation (15 papers). J. Harvey Turner collaborates with scholars based in Australia, United States and United Kingdom. J. Harvey Turner's co-authors include Phillip G. Claringbold, R. Arlen Price, Stefan Winkler, Chun C. Kao, Murali Kesavan, James N. Long, Michael F. Leahy, Danielle Meyrick, Nat Lenzo and J Bouček and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

J. Harvey Turner

96 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Harvey Turner Australia 29 808 753 714 514 390 101 2.6k
Brian T. Collins United States 36 1.1k 1.4× 682 0.9× 511 0.7× 135 0.3× 1.6k 4.2× 231 4.9k
Hirokazu Kawano Japan 31 556 0.7× 397 0.5× 492 0.7× 767 1.5× 462 1.2× 128 3.3k
Arun Malhotra India 39 708 0.9× 1.2k 1.6× 565 0.8× 387 0.8× 949 2.4× 253 5.9k
Yuji Ueda Japan 35 517 0.6× 308 0.4× 257 0.4× 203 0.4× 316 0.8× 166 3.4k
Ulrich Hohenleutner Germany 30 529 0.7× 396 0.5× 449 0.6× 175 0.3× 289 0.7× 154 2.8k
Matthew Foote Australia 28 859 1.1× 370 0.5× 350 0.5× 78 0.2× 608 1.6× 131 2.4k
Peter J. Anderson Australia 37 336 0.4× 336 0.4× 271 0.4× 184 0.4× 352 0.9× 230 4.9k
Ramachandran Murali United States 37 1.5k 1.8× 830 1.1× 354 0.5× 107 0.2× 287 0.7× 163 5.0k
Takashi Koyama Japan 38 505 0.6× 964 1.3× 352 0.5× 149 0.3× 908 2.3× 168 4.6k
Peter Bannas Germany 30 537 0.7× 1.5k 2.0× 658 0.9× 218 0.4× 935 2.4× 186 3.7k

Countries citing papers authored by J. Harvey Turner

Since Specialization
Citations

This map shows the geographic impact of J. Harvey Turner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Harvey Turner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Harvey Turner more than expected).

Fields of papers citing papers by J. Harvey Turner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Harvey Turner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Harvey Turner. The network helps show where J. Harvey Turner may publish in the future.

Co-authorship network of co-authors of J. Harvey Turner

This figure shows the co-authorship network connecting the top 25 collaborators of J. Harvey Turner. A scholar is included among the top collaborators of J. Harvey Turner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Harvey Turner. J. Harvey Turner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Turner, J. Harvey. (2022). Philosophy of Cancer Theranostics. Cancer Biotherapy and Radiopharmaceuticals. 38(1). 1–7. 2 indexed citations
3.
4.
Kesavan, Murali & J. Harvey Turner. (2021). Myeloid Toxicity of Radionuclide Cancer Therapy. Cancer Biotherapy and Radiopharmaceuticals. 37(3). 164–172. 2 indexed citations
5.
Turner, J. Harvey. (2021). Responsible Radionuclide Cancer Care. Cancer Biotherapy and Radiopharmaceuticals. 36(8). 617–623. 1 indexed citations
6.
Cabrini, Stefano, Peter Fischer, Noah Kent, et al.. (2021). Ferromagnetic resonances in single-crystal yttrium iron garnet nanofilms fabricated by metal-organic decomposition. Applied Physics Letters. 119(17). 5 indexed citations
7.
Turner, J. Harvey. (2020). Ethics of Pharma Clinical Trials in the Era of Precision Oncology. Cancer Biotherapy and Radiopharmaceuticals. 36(1). 1–9. 1 indexed citations
8.
Armstrong, Maxim, et al.. (2019). Microscale Fluid Behavior during Cryo-EM Sample Blotting. Biophysical Journal. 118(3). 708–719. 40 indexed citations
9.
Kesavan, Murali, et al.. (2018). Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice. Cancer Biotherapy and Radiopharmaceuticals. 33(7). 274–281. 21 indexed citations
10.
Kesavan, Murali & J. Harvey Turner. (2016). Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience. Cancer Biotherapy and Radiopharmaceuticals. 31(6). 189–198. 53 indexed citations
11.
Claringbold, Phillip G. & J. Harvey Turner. (2015). NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study. Cancer Biotherapy and Radiopharmaceuticals. 30(6). 261–269. 74 indexed citations
12.
Claringbold, Phillip G. & J. Harvey Turner. (2015). Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination <sup>177</sup>Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy. Neuroendocrinology. 103(5). 432–439. 79 indexed citations
13.
Claringbold, Phillip G., R. Arlen Price, & J. Harvey Turner. (2012). Phase I-II Study of Radiopeptide 177 Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors. Cancer Biotherapy and Radiopharmaceuticals. 27(9). 561–569. 131 indexed citations
14.
Krüger, Paul, Julian Cooney, & J. Harvey Turner. (2012). Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma. Cancer Biotherapy and Radiopharmaceuticals. 27(9). 552–560. 7 indexed citations
15.
Turner, J. Harvey. (2012). Perspective: Multimodality Radionuclide Therapy of Progressive Disseminated Lymphoma and Neuroendocrine Tumors as a Paradigm for Cancer Control. Cancer Biotherapy and Radiopharmaceuticals. 27(9). 525–529. 1 indexed citations
16.
Turner, J. Harvey, et al.. (2011). Automated Module Radiolabeling of Peptides and Antibodies with Gallium-68, Lutetium-177 and Iodine-131. Cancer Biotherapy and Radiopharmaceuticals. 27(1). 72–76. 29 indexed citations
17.
Cizek, Pavel, et al.. (2011). The Use of Fe-30% Ni and Fe-30% Ni–Nb Alloys as Model Systems for Studying the Microstructural Evolution during the Hot Deformation of Austenite. Materials and Manufacturing Processes. 26(1). 127–131. 11 indexed citations
18.
19.
Turner, J. Harvey. (1983). Post-traumatic avascular necrosis of the femoral head predicted by preoperative technetium-99m antimony-colloid scan. An experimental and clinical study.. PubMed. 65(6). 786–96. 16 indexed citations
20.
Papadimitriou, J. M., et al.. (1980). Technetium-99m antimony colloid for bone-marrow imaging.. PubMed. 21(11). 1035–41. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian T. Collins Breakdown of academic impact, for papers by Hirokazu Kawano Breakdown of academic impact, for papers by Arun Malhotra Breakdown of academic impact, for papers by Yuji Ueda Breakdown of academic impact, for papers by Ulrich Hohenleutner Breakdown of academic impact, for papers by Matthew Foote Breakdown of academic impact, for papers by Peter J. Anderson Breakdown of academic impact, for papers by Ramachandran Murali Breakdown of academic impact, for papers by Takashi Koyama Breakdown of academic impact, for papers by Peter Bannas
Rankless by CCL
2026